



Dr Peter Mol received his PharmD from the University of Utrecht. On April 27, 2005 he defended successfully his PhD thesis titled 'The Quest for Optimal Antimicrobial Therapy' [PDF] at the University of Groningen. This thesis described an implementation program to strengthen the use of evidence based guidelines for antimicrobial therapy in the UMCG. He continued as a post-doc managing a ZonMW supported implementation study of a Computerized Physician Order Entry system in two hospitals (UMCG and TweeSteden Ziekenhuis Tilburg) and its effects on medication errors and patient safety. This study resulted in a thesis 'Medication errors and adverse drug events in hospitalized patients; methodological issues and computerized intervention' by J. van Doormaal (2009).

In 2003 Peter started working for the Dutch Medicines Evaluation Board (CBG-MEB) and currently holds a position as a senior clinical (pharmacology) assessor with a focus on cardiovascular products. He is since 2009 an alternate member to the European Medicines Agency Scientific Advice Working Party.

In 2007 he initiated two new projects, the first focuses on risk communication of newly identified serious safety issues by regulatory authorities [PhD student; Sigrid Piening]. The second project studies how regulatory authorities deal with safety issues in the regulatory process and whether benefit/risk considerations of regulators are in line with healthcare professionals and patients [PhD student Arna Arnardóttir]. This project is performed in the framework of the TI-Pharma Escher program.

His research now focuses on risk management and risk communication in the drug regulatory process, bridging both his academic and regulatory work. Since 2009 he has an appointment as assistant professor at the Department.

Peter Mol is also a member of the executive committee of EuroDURG (European Drug Utilization Researchers), the SIG-DUR of the International Society of Pharmacoepidemiology, the editorial Board of CORE Evidence journal and a working group of the 'Instituut voor Verantwoord Medicijngebruik'.